In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”

Detalles Bibliográficos
Autores principales: Inaba, Masaaki, Une, Yotaro, Ikejiri, Kazuaki, Kanda, Hironori, Fukagawa, Masafumi, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263242/
https://www.ncbi.nlm.nih.gov/pubmed/35812269
http://dx.doi.org/10.1016/j.ekir.2022.05.023
_version_ 1784742686868111360
author Inaba, Masaaki
Une, Yotaro
Ikejiri, Kazuaki
Kanda, Hironori
Fukagawa, Masafumi
Akizawa, Tadao
author_facet Inaba, Masaaki
Une, Yotaro
Ikejiri, Kazuaki
Kanda, Hironori
Fukagawa, Masafumi
Akizawa, Tadao
author_sort Inaba, Masaaki
collection PubMed
description
format Online
Article
Text
id pubmed-9263242
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92632422022-07-09 In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’” Inaba, Masaaki Une, Yotaro Ikejiri, Kazuaki Kanda, Hironori Fukagawa, Masafumi Akizawa, Tadao Kidney Int Rep Letter to the Editor Elsevier 2022-06-01 /pmc/articles/PMC9263242/ /pubmed/35812269 http://dx.doi.org/10.1016/j.ekir.2022.05.023 Text en © 2022 Published by Elsevier, Inc., on behalf of the International Society of Nephrology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter to the Editor
Inaba, Masaaki
Une, Yotaro
Ikejiri, Kazuaki
Kanda, Hironori
Fukagawa, Masafumi
Akizawa, Tadao
In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
title In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
title_full In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
title_fullStr In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
title_full_unstemmed In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
title_short In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
title_sort in reply to “letter regarding ‘dose-response of tenapanor in patients with hyperphosphatemia undergoing hemodialysis in japan—a phase 2 randomized trial’”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263242/
https://www.ncbi.nlm.nih.gov/pubmed/35812269
http://dx.doi.org/10.1016/j.ekir.2022.05.023
work_keys_str_mv AT inabamasaaki inreplytoletterregardingdoseresponseoftenapanorinpatientswithhyperphosphatemiaundergoinghemodialysisinjapanaphase2randomizedtrial
AT uneyotaro inreplytoletterregardingdoseresponseoftenapanorinpatientswithhyperphosphatemiaundergoinghemodialysisinjapanaphase2randomizedtrial
AT ikejirikazuaki inreplytoletterregardingdoseresponseoftenapanorinpatientswithhyperphosphatemiaundergoinghemodialysisinjapanaphase2randomizedtrial
AT kandahironori inreplytoletterregardingdoseresponseoftenapanorinpatientswithhyperphosphatemiaundergoinghemodialysisinjapanaphase2randomizedtrial
AT fukagawamasafumi inreplytoletterregardingdoseresponseoftenapanorinpatientswithhyperphosphatemiaundergoinghemodialysisinjapanaphase2randomizedtrial
AT akizawatadao inreplytoletterregardingdoseresponseoftenapanorinpatientswithhyperphosphatemiaundergoinghemodialysisinjapanaphase2randomizedtrial

Ejemplares similares